NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
2023年12月6日 - 8:50PM
ビジネスワイヤ(英語)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its
partnership with Woo University to support the education of eyecare
professionals on the use of amniotic membranes. A free webinar is
being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific
time, and eyecare professionals can register here. In September
2023 NovaBay commercially launched its prescription amniotic
membrane product Avenova® Allograft, which is intended for use as a
protective covering during the repair of ocular surfaces.
The optometric continuing education (CE)-credit webinar will
feature host Dr. Stephanie Woo,
moderator Dr. Elise Kramer, and sponsor presenter Dr. Maria
Sampalis discussing the role of amniotic membranes in treating a
variety of ocular surface conditions, candidate selection, and
billing and coding. The webinar will also feature case reports
demonstrating the healing power of amniotic membranes. Woo
University is a non-profit organization committed to providing
high-quality continuing education to eyecare professionals around
the world.
“This webinar is intended to provide optometrists with useful
information about how to incorporate amniotic membranes into their
practices while providing NovaBay with the opportunity to create
further awareness of our high-quality product among our targeted
customer base,” said Justin Hall, CEO and General Counsel of
NovaBay. “This event is just one of a number of outreach programs
aimed at educating eyecare specialists on the clinical benefits of
the Avenova Allograft, which we believe will be important in
positioning and differentiating our product among prospective
customers.”
The Avenova® Allograft provides a protective environment or
covering for repair of the cornea and conjunctiva, helping ocular
surface to return to a healthier state. It is the only optic
allograft manufactured using the patented six-step BioREtain®
process that preserves the natural integrity of the placental
tissue. The product consists only of the amnion layer of the
placental membrane and measures between 20-50 microns thick, making
it ideal for delicate ophthalmic applications. Avenova Allograft is
available in 8mm, 10mm and 12mm diameter sizes. The Avenova
Allograft competes in a global market estimated at $403.6 million
in 2022, which is expected to grow at 9.8% per year between
2023-2030. Eyecare professionals can order Avenova Allograft
directly on Avenova.com.
In addition to the allograft product, NovaBay’s Avenova suite of
products include Avenova antimicrobial lid and lash spray,
specially designed dry wipes, lubricating eye drops, a warm eye
compress, oral supplements and the i-Chek mirror to monitor
physical eyelid health.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare, skincare and wound care
products. NovaBay’s leading product Avenova® Antimicrobial Lid
& Lash Solution is often prescribed by eyecare professionals
for blepharitis and dry-eye disease and is also available directly
to consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 dermatologist-developed skincare
products through the DERMAdoctor website, well-known traditional
and digital beauty retailers, and international distributors.
NovaBay also manufactures and sells effective, yet gentle and
non-irritating wound care products. The PhaseOne® brand is
distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited. More information
about NovaBay is available here.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231206343112/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 5 2024 まで 6 2024
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 6 2023 まで 6 2024